APA Alıntı

McEwan, P., Webster, S., Ward, T., Brenner, M., Kalsekar, A., & Yuan, Y. (2017). Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus. Cost Eff Resour Alloc.

Chicago Stili Alıntı

McEwan, Phil, Samantha Webster, Thomas Ward, Michael Brenner, Anupama Kalsekar, ve Yong Yuan. "Estimating the Cost-effectiveness of Daclatasvir + sofosbuvir Versus Sofosbuvir + ribavirin for Patients With Genotype 3 Hepatitis C Virus." Cost Eff Resour Alloc 2017.

MLA Alıntı

McEwan, Phil, et al. "Estimating the Cost-effectiveness of Daclatasvir + sofosbuvir Versus Sofosbuvir + ribavirin for Patients With Genotype 3 Hepatitis C Virus." Cost Eff Resour Alloc 2017.